Search results for "Cell transplantation"

showing 10 items of 493 documents

Clinicogenetic Risk Models in Patients Randomized to Receive Consolidative Autologous Stem-Cell Transplantation after Frontline R-CHOP for Advanced F…

2018

Abstract Introduction: Advanced follicular lymphoma (FL) is a clinically and molecularly heterogeneous disease. About 20% of patients have early progression of disease (POD) and short overall survival (OS). We have previously shown that integration of lymphoma-specific gene mutations and clinical factors improves pretreatment risk stratification (Pastore, 2015) and prediction of early POD (i.e., within 24 months, POD24; Jurinovic, 2016). Recently, we have shown that high-dose therapy (HDT) followed by autologous stem-cell transplantation (ASCT) is an effective treatment option for eligible patients with high-risk disease as defined by POD24 (Jurinovic, 2018). Here, we aimed to explore wheth…

medicine.medical_specialtyIntention-to-treat analysisbusiness.industryImmunologyFollicular lymphomaCell BiologyHematologyGene mutationmedicine.diseaseBiochemistryTransplantationAutologous stem-cell transplantationInternational Prognostic IndexInternal medicineCohortmedicineIn patientbusinessBlood
researchProduct

The effect of timing on community acquired respiratory virus infection mortality during the first year after allogeneic hematopoietic stem cell trans…

2019

The effect of timing of community acquired respiratory virus (CARV) infection after allogeneic hematopoietic stem cell transplant (allo-HCT) is an as yet unsettled issue. We evaluate this issue by including all consecutive allo-HCT recipients with molecularly-documented CARV infection during the first year after transplant. The study cohort was drawn from a prospective longitudinal survey of CARV in allo-HCT recipient having respiratory symptoms conducted from December 2013 to December 2018 at two Spanish transplant centers. Respiratory viruses in upper and/or lower respiratory specimens were tested using multiplex PCR panel assays. The study cohort comprised 233 allo-HCT recipients with 37…

medicine.medical_specialtyMultivariate analysisEpidemiologymedicine.medical_treatmentHematopoietic stem cell transplantationArticle03 medical and health sciences0302 clinical medicineInternal medicineEpidemiologymedicineHumansProspective StudiesRespiratory systemRespiratory Tract InfectionsTransplantationbusiness.industryHematopoietic Stem Cell TransplantationHematologyOdds ratioConfidence intervalStem-cell researchVirus Diseases030220 oncology & carcinogenesisCohortVirusesRespiratory virusbusiness030215 immunologyBone marrow transplantation
researchProduct

Engraftment kinetics of human CD34+ cells from cord blood and mobilized peripheral blood co-transplanted into NOD/SCID mice

2004

We have reported short periods of post transplant neutropenia in human patients co-transplanted with cord blood (CB) and low numbers of haploidentical mobilized peripheral blood (MPB) CD34+ cells. To investigate the effect that the proportion of MPB to CB cells may have on engraftment kinetics, we have co-transplanted fixed numbers of human CB CD34+ cells mixed with different numbers of MPB CD34+ cells into NOD/SCID mice. We periodically quantified the proportion of human cells and the relative contribution of MPB and CB cells to the human engraftment on marrow aspirates. At the lowest MPB/CB ratios (5 : 1, 10 : 1), the contribution of CB cells predominated at all time points analyzed, and …

medicine.medical_specialtyNeutropeniaTransplantation HeterologousCD34Antigens CD34Mice SCIDCord Blood Stem Cell TransplantationNeutropeniaBlood cellMiceAntigenMice Inbred NODInternal medicinemedicineAnimalsHumansPeripheral Blood Stem Cell TransplantationTransplantationHematologybusiness.industryGraft SurvivalHematologymedicine.diseaseMolecular biologyTransplantationKineticsmedicine.anatomical_structureCord bloodModels AnimalImmunologyCord Blood Stem Cell TransplantationbusinessBone Marrow Transplantation
researchProduct

Obstetric and offspring risks of women’s morbid conditions linked to prior anticancer treatments

2016

Background Literature shows the effects of type of cancer and/or anticancer treatment on live birth percentages and/or pregnancy and neonatal complications in female cancer survivors. However, studies analyzing the obstetric and offspring risks of the morbid conditions associated with previous anti-cancer treatments are missing. The present review aims to uncover these risks. Methods A literature search based on publications up to March 2016 identified by PubMed and references cited in relevant articles. Results The morbid conditions associated with prior anticancer treatments including chemotherapy, radiotherapy, surgery, and/or hematopoietic stem-cell transplant may induce not only obstet…

medicine.medical_specialtyOffspringmedia_common.quotation_subjectReproductive medicineAntineoplastic AgentsFertilityReview03 medical and health sciences0302 clinical medicineEndocrinologyPregnancyRisk FactorsNeoplasmsmedicineHumansProspective StudiesProspective cohort studymedia_commonPregnancy030219 obstetrics & reproductive medicineRadiotherapyObstetricsbusiness.industryHematopoietic Stem Cell TransplantationObstetrics and GynecologyCancerDelivery Obstetricmedicine.diseaseFertilityTreatment OutcomePregnancy complicationsReproductive MedicineGynecologyPrenatal Exposure Delayed Effects030220 oncology & carcinogenesisGestationFemalebusinessLive birthGestationDevelopmental BiologyReproductive Biology and Endocrinology
researchProduct

Strategies for managing Asherman's syndrome and endometrial atrophy: Since the classical experimental models to the new bioengineering approach

2021

Endometrial function is essential for embryo implantation and pregnancy, but managing endometrial thickness that is too thin to support pregnancy or an endometrium of compromised functionality due to intrauterine adhesions is an ongoing challenge in reproductive medicine. Here, we review current and emerging therapeutic and experimental options for endometrial regeneration with a focus on animal models used to study solutions for Asherman's syndrome and endometrial atrophy, which both involve a damaged endometrium. A review of existing literature was performed that confirmed the lack of consensus on endometrial therapeutic options, though promising new alternatives have emerged in recent ye…

medicine.medical_specialtyPregnancyPlatelet-Rich PlasmaRegeneration (biology)Reproductive medicineAsherman's syndromeGynatresiaCell BiologyBiologymedicine.diseaseBioinformaticsEndometriumENDOMETRIAL ATROPHYClinical trialDisease Models AnimalEndometriummedicine.anatomical_structureGeneticsmedicineAnimalsHumansFemaleStem cellStem Cell TransplantationDevelopmental BiologyMolecular Reproduction and Development
researchProduct

High-Dose Therapy and Autologous Hematopoietic Stem Cell Transplantation (ASCT) Has a Significant but Transient Impact on Quality of Life: Lessons Fr…

2011

Abstract Abstract 1989 Objective: High-dose therapy (HDT) and ASCT is the standard of care in a variety of hematologic malignancies. Whereas for some indications a survival advantage for HDT and ASCT has been demonstrated, a benefit only in terms of better progression-free survival has been shown for CLL. Because of this the quality of life (QoL) deserves particular attention. QoL assessment was a major focus of a randomized controlled EBMT-Intergroup trial on the value of HDT compared to observation in first or second remission of CLL (Michallet, Blood, 2011). Methods: 222 patients were enrolled into the study and allocated to either ASCT or observation. In the transplant arm, 72% received…

medicine.medical_specialtyRandomizationIntention-to-treat analysisbusiness.industrymedicine.medical_treatmentChronic lymphocytic leukemiaImmunologyCell BiologyHematologyHematopoietic stem cell transplantationmedicine.diseaseBiochemistryTransplantationQuality of lifeChronic leukemiaInternal medicineCohortmedicinebusiness
researchProduct

Transplantation of Mesenchymal Stem Cells Exerts a Greater Long-Term Effect than Bone Marrow Mononuclear Cells in a Chronic Myocardial Infarction Mod…

2010

The aim of this study is to assess the long-term effect of mesenchymal stem cells (MSC) transplantation in a rat model of chronic myocardial infarction (MI) in comparison with the effect of bone marrow mononuclear cells (BM-MNC) transplant. Five weeks after induction of MI, rats were allocated to receive intramyocardial injection of 106 GFP-expressing cells (BM-MNC or MSC) or medium as control. Heart function (echocardiography and 18F-FDG-microPET) and histological studies were performed 3 months after transplantation and cell fate was analyzed along the experiment (1 and 2 weeks and 1 and 3 months). The main findings of this study were that both BM-derived populations, BM-MNC and MSC, ind…

medicine.medical_specialtyTime FactorsAngiogenesisMyocardial InfarctionBiomedical Engineeringlcsh:Medicine030204 cardiovascular system & hematologyMesenchymal Stem Cell TransplantationPeripheral blood mononuclear cellTimeRats Sprague-DawleyAndrology03 medical and health sciences0302 clinical medicineInternal medicinemedicineAnimalsRegenerationChronic myocardial infarctionCells CulturedCardiac remodelingBone Marrow Transplantation030304 developmental biologyStem cell transplantation for articular cartilage repair0303 health sciencesTransplantationBone marrow stem cellsVentricular Remodelingbusiness.industryMyocardiumlcsh:RMesenchymal stem cellBone Marrow Stem CellCell BiologyRatsEndothelial stem cellTransplantationDisease Models AnimalTreatment Outcomemedicine.anatomical_structureChronic DiseaseCardiologyFemaleAngiogenesisBone marrowbusinessCell Transplantation
researchProduct

Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommenda…

2020

Graft-versus-host disease (GVHD) is a major factor contributing to mortality and morbidity after allogeneic stem-cell transplantation. Because of the small number of results from well designed, large- scale, clinical studies there is considerable variability in the prevention and treatment of GVHD worldwide. In 2014, to standardise treatment approaches the European Society of Blood and Marrow Transplantation published recommendations on the management of GVHD in the setting of HLA-identical sibling or unrelated donor transplantation in adult patients with haematological malignancies. Here we update these recommendations including the results of study published after 2014. Evidence was searc…

medicine.medical_specialtyTransplantation ConditioningDrug ResistanceMEDLINEGraft vs Host DiseaseBronchiolitis obliteransDisease03 medical and health sciences0302 clinical medicinegraft versus host diseasemedicineHumansDisease management (health)Intensive care medicineImmunosuppression Therapybusiness.industryDisease ManagementHematologymedicine.disease3. Good healthAnti-thymocyte globulinTransplantationSystematic reviewGraft-versus-host diseasesurgical procedures operativeHematologic Neoplasms030220 oncology & carcinogenesisDrug MonitoringbusinessImmunosuppressive AgentsStem Cell Transplantation030215 immunology
researchProduct

Combining Three Different Pretransplantation Scores Improves Predictive Value in Patients after Haploidentical Stem Cell Transplantation with Thiotep…

2021

ABSTRACT One hundred and sixty-one patients underwent haploidentical stem cell transplantation (haploSCT) with thiotepa, busulfan, and fludarabine conditioning followed by post-transplantation cyclophosphamide (PTCy) (on days +3 and +4) and tacrolimus as graft-versus-host disease prophylaxis. Forty-two percent of patients had a high or very high revised Disease Risk Index (rDRI), 55% had an European Society for Blood and Marrow Transplantation risk score (EBMT-RS) ≥4, and 36% had an age-adjusted Hematopoietic Cell Transplant Comorbidity Index (HCT-CI-age) score ≥3. Each of these was considered an unfavorable score. Using the pretransplantation unfavorable scores that had an independent impa…

medicine.medical_specialtyTransplantation ConditioningPredictive transplantation scoresCyclophosphamideAcute myelogenous leukemiaGraft vs Host DiseaseThioTEPAInternal medicinemedicineHumansImmunology and AllergyBusulfanCyclophosphamideTransplantationFramingham Risk Scorebusiness.industryIncidence (epidemiology)Hematopoietic Stem Cell TransplantationCell BiologyHematologyHaploidentical transplantation with TBF conditioningTacrolimusFludarabineTransplantationsurgical procedures operativeMolecular MedicinebusinessThiotepaVidarabineBusulfanmedicine.drugTransplantation and Cellular Therapy
researchProduct

Oral complaints in patients with acute myeloid leukemia treated with allogeneic hematopoietic stem cell transplantation

2021

Background Acute myeloid leukemia belongs to proliferative diseases of the hematopoietic system. It is currently the leading indication for allogeneic hematopoietic stem cell transplantation. This study was designed to determine the most common subjective oral mucosa complaints in patients with acute myeloid leukemia after allogeneic hematopoietic cell transplantation, in relation to the type of conditioning used. Material and Methods Eighty patients diagnosed with acute myeloid leukemia were assigned to two groups depending on the intensity of the conditioning regimen before transplantation: myeloablative and reduced-intensity chemotherapy. The oral symptoms were evaluated based on an auth…

medicine.medical_specialtyTransplantation Conditioningmedicine.medical_treatmentGraft vs Host DiseaseHematopoietic stem cell transplantationInternal medicineMedicineHumanstumor microenvironmentdendritic cellsOral mucosaGeneral DentistryUNESCO:CIENCIAS MÉDICASRetrospective StudiesChemotherapyOral Medicine and Pathologybusiness.industryResearchHematopoietic Stem Cell TransplantationMyeloid leukemiaoral cancerDysgeusiaTransplantationclec9aHaematopoiesisLeukemia Myeloid Acutemedicine.anatomical_structureOtorhinolaryngologyTaste disorderQuality of LifeSurgeryimmunotherapymedicine.symptombusiness
researchProduct